Mylan in the UK

Mylan ranks among the leading global generic and specialty pharmaceutical companies. Ranked number 3 in the UK generic prescription market, Mylan maintains one of the industry’s broadest and highest quality portfolios, with around 1,400 high quality generic, branded and over-the-counter products globally, covering most available dosage forms and a big range of therapeutic categories.

At Mylan we have one global quality standard in everything we do. Our internal teams conduct reviews of all products, start to finish. No matter where in the world they are made.

Why such high standards? Because we truly care about the people who will be helped by the medicines we make. And we believe in earning that trust from physicians, pharmacists, other health care professionals and patients, every day. It’s why we say, “Our Mylan is Your Mylan.”

Want to know more about generic medicines? See the facts, figures, and bioequivalence details below.

  • 67% Market Share

    Generic products have a 67% market share in the UK, with generic prices in the UK the lowest in the developed world and constrained by free market competition1

  • MHRA and EMA

    The UK Medicines and Healthcare Products Regulatory Agency (MHRA) and/or the European Medicines Agency (EMA), assess quality, safety and efficacy and approve every medicine before it can be sold in the UK

  • Bioequivalence

    To gain MHRA and EMA approval, generic medicines must be proven to be bioequivalent to their brand name counterparts. That means generic and brand name medicines are essentially the same in the following ways:

    • Active ingredient
    • Maximum amount of medicine in the blood at any given time
    • Total amount of medicine in the blood from the time it is taken until the body eliminates it
    • Strength and dosage
    • Route of administration – orally, intravenously etc.
    • Expected safety and efficacy
    • MHRA and EMA evaluation of manufacturing facilities

    Just because products have the same active ingredient does not mean they are bioequivalent. Once generic bioequivalence is proven, the MHRA or EMA grant a licence to market and sell the product. Find out more about generic medicines here: and

  • £12 Billion

    The use of generic medicines already saves the NHS over £12bn per year2

  • There are two main factors behind the popularity of generics

    • – According to the BGMA, generic medicines are between 20% to 90% less costly than the original price of their brand-name equivalents
    • – National health authorities can free up much needed financial resources and reallocate them to other areas of the healthcare system needing prioritisation
  • Innovation

    Innovation is the key to Mylan’s ability to bring new products to market, including medicines that are difficult-to-manufacture and difficult-to-formulate. Find out about our therapeutic innovation.
Last Updated  04/08/2017